The American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) algorithm for managing glycaemia in patients with type 2 diabetes mellitus: comparison with the ADA/EASD algorithm

Rodbard, Helena W.; Jellinger, Paul S.

doi:10.1007/s00125-010-1905-7

Cited by 12 publications

(6 citation statements)

References 8 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most anti-diabetic agents lower blood glucose levels via an insulin-dependent mechanism; however, due to the progressive nature of beta-cell dysfunction in type 2 diabetes [1], the efficacy of these agents is compromised over time [2]. A combination of two or more classes of anti-diabetic agent is more likely to achieve long-term glycaemic control in patients with type 2 diabetes compared to monotherapy [20]. SGLT2 inhibitors, such as empagliflozin, represent a new class of oral anti-diabetic agents that act via a novel insulin-independent mode of action.…”

Section: Discussionmentioning

confidence: 99%

Pharmacokinetics of Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, and Glimepiride Following Co-administration in Healthy Volunteers: A Randomised, Open-label, Crossover Study

Macha¹,

Mattheus²,

Pinnetti³

et al. 2012

J Diab Res Clin Met

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Pharmacokinetics of Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, and Glimepiride Following Co-administration in Healthy Volunteers: A Randomised, Open-label, Crossover Study

Macha¹,

Mattheus²,

Pinnetti³

et al. 2012

J Diab Res Clin Met

View full text Add to dashboard Cite

show abstract

“…Guidelines for the management of hyperglycaemia in subjects with T2D acknowledge the benefit shown by incretin‐based therapies over traditional OADs in reducing HbA 1c ; as such, they are included in the current treatment algorithms provided by NICE, the American Diabetes Association (ADA)/EASD and American Association of Clinical Endocrinologists (AACE)/American College of Endocrinologists (ACE) . In the UK, NICE considers incretin‐based therapies to be second‐line treatments, to be used when the first‐line therapy is contraindicated and in certain patient populations (Fig.…”

Section: Comparing Glp‐1ras and Dpp‐4is: Efficacy Tolerability And Smentioning

confidence: 99%

Recent advances in incretin‐based therapies

Russell‐Jones

Gough

2012

Clinical Endocrinology

View full text Add to dashboard Cite

SummaryThe global burden of type 2 diabetes is growing. Traditional therapies are suboptimal and there is a clear unmet need for treatments that offer effective glucose control while addressing the comorbid factors associated with diabetes, such as obesity and risk of cardiovascular disease, without the fear of hypoglycaemia. Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors offer a novel way of reducing hyperglycaemia by targeting the incretin system. This review provides an overview of the development of incretin-based therapies and explains their differing modes of action compared with traditional interventions. A comparison of the clinical profiles of current glucagon-like peptide-1 receptor agonists [liraglutide and exenatide (twice-daily and once-weekly)] and dipeptidyl peptidase-4 inhibitors (sitagliptin, saxagliptin, vildagliptin and linagliptin) is performed alongside a discussion of the placement of incretin-based therapies in treatment guidelines. Further improvements in this class are expected, and we will examine some of the novel glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors currently under development.

show abstract

“…The recent development of a number of new medications (Metformin, Pioglitazone) to control blood glucose has enlarged the armamentarium of agents used to treat this disease (21). However, the role of these newer agents has been unclear.…”

Section: Discussionmentioning

confidence: 98%

Serum Ghrelin, Insulin and Glucose Levels are Correlated in Patients with Type 2 Diabetes Mellitus

Eizadi¹

2011

Acta Endo (Buc)

View full text Add to dashboard Cite

Background. The research evidence have suggested that ghrelin, a neuropeptide containing 28 amino acids, plays an important role in glucose homeostasis and its concentration is increased in diabetes.Objective. To investigate the relationship between the serum levels of ghrelin, insulin, fasting glucose and glycated hemoglobin in patients with type 2 diabetes mellitus.Materials and Methods. Fasting glucose, insulin, ghrelin and glycated hemoglobin were measured after a 12-14 hours overnight fasting in 48 adult males with type 2 diabeties. Pearson correlations were used to establish the relationship between ghrelin concentration and other variables. P-value of less than 0.05 was considered statistically significant.Results. There were no correlations between serum ghrelin and Systolic and diastole blood pressure and body mass index (p<0.05). Serum ghrelin is weakly associated with glycated hemoglobin (p=0.076, R=0.19). Serum ghrelin concentrations were positively correlated with fasting glucose (p=0.005, R=0.40). In addition, ghrelin correlated negatively with serum insulin (p=0.013, r=-0.36).Conclusion. Our data demonstrate that high ghrelin concentration is accompanied with increase in blood glucose in type 2 diabetic patients, and support this hypothesis that this neuropeptide plays a pathophysiological role in this disease.

show abstract

The American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) algorithm for managing glycaemia in patients with type 2 diabetes mellitus: comparison with the ADA/EASD algorithm

Cited by 12 publications

References 8 publications

Pharmacokinetics of Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, and Glimepiride Following Co-administration in Healthy Volunteers: A Randomised, Open-label, Crossover Study

Pharmacokinetics of Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, and Glimepiride Following Co-administration in Healthy Volunteers: A Randomised, Open-label, Crossover Study

Recent advances in incretin‐based therapies

Serum Ghrelin, Insulin and Glucose Levels are Correlated in Patients with Type 2 Diabetes Mellitus

Contact Info

Product

Resources

About